OPDUALAG

This brand name is authorized in United States. It is also authorized in Austria, Croatia, France, Israel, Italy, Lithuania.

Active ingredients

The drug OPDUALAG contains a combination of these active pharmaceutical ingredients (APIs):

1	Nivolumab UNII 31YO63LBSN - NIVOLUMAB
	Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb), which binds to the programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2. Nivolumab potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands. In syngeneic mouse models, blocking PD-1 activity resulted in decreased tumour growth.
	Read more about Nivolumab
2	Relatlimab UNII AF75XOF6W3 - RELATLIMAB

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OPDUALAG Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FY02		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FY Combinations of monoclonal antibodies and antibody drug conjugates
Discover more medicines within L01FY02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FR	Base de données publique des médicaments	62235699
IL	מִשְׂרַד הַבְּרִיאוּת	9285
IT	Agenzia del Farmaco	050359013
LT	Valstybinė vaistų kontrolės tarnyba	1095546
US	FDA, National Drug Code	0003-7125